Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Jennifer Laudadio

Concepts (144)

Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Papillomavirus Infections
4
2015
167
1.170
Why?
Papillomaviridae
3
2015
102
0.900
Why?
Keratosis, Seborrheic
2
2015
4
0.590
Why?
Vulvar Diseases
2
2015
7
0.580
Why?
Alphapapillomavirus
2
2014
13
0.540
Why?
Pathology
1
2015
38
0.480
Why?
Fusion Proteins, bcr-abl
3
2009
19
0.460
Why?
Curriculum
2
2022
397
0.440
Why?
Neoplasm Invasiveness
2
2012
269
0.430
Why?
Genomics
1
2015
284
0.430
Why?
Uterine Cervical Dysplasia
1
2013
49
0.420
Why?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
3
2009
42
0.400
Why?
Perineum
1
2012
24
0.400
Why?
Myxoma
1
2012
16
0.390
Why?
Mutagenesis, Insertional
2
2008
24
0.380
Why?
Vulvar Neoplasms
1
2012
58
0.370
Why?
Uterine Cervical Neoplasms
1
2013
277
0.350
Why?
Mass Screening
1
2013
348
0.340
Why?
In Situ Hybridization, Fluorescence
2
2007
256
0.300
Why?
Introns
1
2008
49
0.300
Why?
Protein Kinase Inhibitors
2
2013
205
0.290
Why?
Carcinoma, Squamous Cell
1
2010
330
0.290
Why?
Head and Neck Neoplasms
1
2010
281
0.280
Why?
Genes, erbB-2
1
2007
8
0.280
Why?
Actinomyces
1
2006
9
0.270
Why?
Actinomycosis
1
2006
10
0.270
Why?
Vaginal Smears
1
2006
28
0.270
Why?
Carcinoma, Transitional Cell
1
2005
52
0.250
Why?
Microsatellite Instability
1
2024
18
0.230
Why?
DNA Mismatch Repair
1
2024
16
0.230
Why?
Urinary Bladder Neoplasms
1
2005
158
0.230
Why?
Endometrial Neoplasms
1
2024
137
0.210
Why?
Humans
20
2024
50201
0.200
Why?
DNA, Viral
2
2014
133
0.200
Why?
Polymerase Chain Reaction
2
2014
456
0.190
Why?
Fellowships and Scholarships
1
2022
118
0.180
Why?
Colorectal Neoplasms
1
2024
255
0.180
Why?
Female
13
2024
26829
0.170
Why?
Middle Aged
7
2014
12356
0.150
Why?
Breast Neoplasms
1
2007
1187
0.140
Why?
Gastrointestinal Neoplasms
1
2015
40
0.120
Why?
Prognosis
4
2015
1963
0.120
Why?
Mucositis
1
2014
7
0.120
Why?
Oropharyngeal Neoplasms
1
2014
18
0.120
Why?
Histocytochemistry
1
2014
47
0.110
Why?
Microscopy
1
2014
59
0.110
Why?
Quinazolines
1
2013
32
0.110
Why?
Protein Structure, Tertiary
3
2009
249
0.110
Why?
Human Papillomavirus DNA Tests
1
2013
1
0.110
Why?
Virology
1
2013
6
0.110
Why?
Molecular Diagnostic Techniques
1
2013
33
0.110
Why?
Bile Duct Diseases
1
2013
11
0.110
Why?
United States Food and Drug Administration
1
2013
91
0.100
Why?
Genotype
1
2014
542
0.100
Why?
RNA, Messenger
2
2013
1097
0.100
Why?
Clinical Competence
1
2015
397
0.100
Why?
Phosphotransferases
2
2009
16
0.100
Why?
Aged
5
2014
9505
0.100
Why?
Carcinoma, Non-Small-Cell Lung
1
2013
154
0.100
Why?
Piperazines
2
2009
118
0.090
Why?
Cholelithiasis
1
2011
12
0.090
Why?
Cholecystectomy, Laparoscopic
1
2011
20
0.090
Why?
Pyrimidines
2
2009
192
0.090
Why?
In Situ Hybridization
1
2010
64
0.090
Why?
Smoking
1
2014
506
0.090
Why?
Endosonography
1
2011
94
0.090
Why?
Algorithms
1
2013
615
0.080
Why?
HIV Infections
1
2013
356
0.080
Why?
Diagnosis, Differential
1
2012
1041
0.080
Why?
Exons
1
2008
95
0.080
Why?
United States
2
2022
4898
0.070
Why?
Lung Neoplasms
1
2013
601
0.070
Why?
DNA Mutational Analysis
1
2008
176
0.070
Why?
Adult
6
2022
13486
0.070
Why?
Aged, 80 and over
3
2014
3158
0.070
Why?
Proto-Oncogenes
1
2007
27
0.070
Why?
Gene Amplification
1
2007
57
0.070
Why?
Base Sequence
1
2008
653
0.070
Why?
Amino Acid Sequence
1
2008
576
0.070
Why?
Receptor, erbB-2
1
2007
74
0.070
Why?
Molecular Sequence Data
1
2008
795
0.070
Why?
Male
7
2014
25572
0.070
Why?
Cell Division
1
2007
293
0.070
Why?
Young Adult
2
2013
4052
0.060
Why?
Intestinal Neoplasms
1
2024
8
0.060
Why?
Pathology, Clinical
1
2024
24
0.060
Why?
Immunohistochemistry
1
2007
973
0.060
Why?
Intestine, Small
1
2024
111
0.050
Why?
Mutation
1
2009
1288
0.050
Why?
Antineoplastic Agents
4
2014
1176
0.050
Why?
Sensitivity and Specificity
1
2005
871
0.050
Why?
Retrospective Studies
4
2022
6190
0.050
Why?
Adolescent
3
2011
6459
0.050
Why?
Disease-Free Survival
2
2014
450
0.050
Why?
Esophageal Neoplasms
1
2024
104
0.050
Why?
Pathology, Molecular
1
2022
22
0.050
Why?
Accreditation
1
2022
59
0.050
Why?
Neoplasm Recurrence, Local
1
2005
630
0.050
Why?
Combined Modality Therapy
2
2014
639
0.040
Why?
Reproducibility of Results
1
2024
1195
0.040
Why?
Education, Medical, Graduate
1
2022
213
0.040
Why?
Treatment Outcome
3
2014
5203
0.040
Why?
Benzamides
2
2009
50
0.040
Why?
Molecular Imaging
1
2015
54
0.030
Why?
Cyclin D3
1
2013
5
0.030
Why?
Survival
1
2013
12
0.030
Why?
Taxoids
1
2013
37
0.030
Why?
Cyclin D1
1
2013
56
0.030
Why?
Granulocyte Colony-Stimulating Factor
1
2013
60
0.030
Why?
Radiotherapy
1
2014
124
0.030
Why?
Polyethylene Glycols
1
2013
86
0.030
Why?
Anti-Retroviral Agents
1
2013
13
0.030
Why?
Liver Cirrhosis, Biliary
1
2013
11
0.030
Why?
Jaundice
1
2013
19
0.030
Why?
Patient Compliance
1
2014
230
0.030
Why?
Drug Administration Schedule
1
2013
369
0.030
Why?
Cholestasis
1
2013
40
0.030
Why?
Syndrome
1
2013
239
0.020
Why?
Recombinant Proteins
1
2013
480
0.020
Why?
Cisplatin
1
2013
275
0.020
Why?
CD4-Positive T-Lymphocytes
1
2013
157
0.020
Why?
Technetium Tc 99m Lidofenin
1
2011
1
0.020
Why?
Ursodeoxycholic Acid
1
2011
5
0.020
Why?
Cholagogues and Choleretics
1
2011
6
0.020
Why?
Cholangiography
1
2011
11
0.020
Why?
Cholangiopancreatography, Magnetic Resonance
1
2011
9
0.020
Why?
False Negative Reactions
1
2011
29
0.020
Why?
Ceftriaxone
1
2011
26
0.020
Why?
Age of Onset
1
2011
108
0.020
Why?
Biopsy
1
2013
592
0.020
Why?
Antibiotic Prophylaxis
1
2011
61
0.020
Why?
Radiography, Interventional
1
2011
57
0.020
Why?
Pancreatitis
1
2011
58
0.020
Why?
Neurosurgical Procedures
1
2011
122
0.020
Why?
Gene Expression Regulation, Leukemic
1
2009
32
0.020
Why?
Comorbidity
1
2011
612
0.020
Why?
Up-Regulation
1
2009
446
0.020
Why?
Antineoplastic Combined Chemotherapy Protocols
1
2013
1000
0.020
Why?
Transcription, Genetic
1
2008
369
0.020
Why?
Liver
1
2013
1122
0.020
Why?
Follow-Up Studies
1
2011
2188
0.020
Why?
Tomography, X-Ray Computed
1
2011
1160
0.020
Why?
Postoperative Complications
1
2011
1027
0.010
Why?
Child
1
2011
6862
0.010
Why?
Laudadio's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_